{
  "url": "https://openlegislation.uk/eu-regulation-2013-944/annex-III",
  "json_url": "https://openlegislation.uk/eu-regulation-2013-944/annex-III.json",
  "legislation": "eur/2013/944",
  "legislation_title": "Commission Regulation (EU) No 944/2013 of 2 October 2013 amending, for the purposes of its adaptation to technical and scientific progress, Regulation (EC) No 1272/2008 of the European Parliament and of the Council on classification, labelling and packaging of substances and mixtures (Text with EEA relevance)",
  "legislation_url": "https://openlegislation.uk/eu-regulation-2013-944",
  "path": "annex/III",
  "kind": "annex",
  "number": "III",
  "heading": null,
  "text": "Index No\nInternational Chemical Identification\nEC No\nCAS No\nClassification\nLabelling\nSpecific Conc. Limits,M — Factors\nNotes\nHazard Class and Category Code(s)\nHazard statement Code(s)\nPictogram, Signal Word Code(s)\nHazard statement Code(s)\nSuppl. Hazard statement Code(s)\n031-001-00-4\ngallium arsenide\n215-114-8\n1303-00-0\nCarc. 1B\nH350\nGHS08\nH350\nSTOT RE 1\nH372 (respiratory and haematopoietic systems)\nDgr\nH372 (respiratory and haematopoietic systems)\n050-025-00-6\ntrichloromethylstannane\n213-608-8\n993-16-8\nRepr. 2\nH361d\nGHS08\nWng\nH361d\n050-026-00-1\n2-ethylhexyl 10-ethyl-4-[[2-[(2-ethylhexyl)oxy]-2-oxoethyl]thio]-4-methyl-7-oxo-8-oxa-3,5-dithia-4-stannatetradecanoate\n260-828-5\n57583-34-3\nRepr. 2\nH361d\nGHS08\nWng\nH361d\n050-027-00-7\n2-ethylhexyl 10-ethyl-4,4-dioctyl-7-oxo-8-oxa-3,5-dithia-4-stannatetradecanoate\n239-622-4\n15571-58-1\nRepr. 1B\nH360D\nGHS08\nDgr\nH360D\n601-087-00-3\n2,4,4-trimethylpentene\n246-690-9\n25167-70-8\nFlam. Liq. 2\nH225\nGHS02\nH225\nD\nAsp. Tox. 1\nH304\nGHS07\nH304\nSTOT SE 3\nH336\nGHS08\nDgr\nH336\n606-145-00-1\nsulcotrione (ISO);\n2-[2-chloro-4-(methylsulfonyl)benzoyl]cyclohexane-1,3-dione\n99105-77-8\nRepr. 2\nH361d\nGHS08\nH361d\nM = 1\nM = 10\nSTOT RE 2\nH373 (kidneys)\nGHS07\nH373 (kidneys)\nSkin Sens. 1A\nH317\nGHS09\nH317\nAquatic Acute 1\nH400\nWng\nAquatic Chronic 1\nH410\nH410\n607-699-00-7\nbifenthrin (ISO);\n(2-methylbiphenyl-3-yl)methyl rel-(1R,3R)-3-[(1Z)-2-chloro-3,3,3-trifluoroprop-1-en-1-yl]-2,2-dimethylcyclopropanecarboxylate\n82657-04-3\nCarc. 2\nH351\nGHS06\nH351\nM = 10 000\nM = 100 000\nAcute Tox. 3\nH331\nGHS08\nH331\nAcute Tox. 2\nH300\nGHS09\nH300\nSTOT RE 1\nH372 (nervous system)\nDgr\nH372 (nervous system)\nSkin Sens. 1B\nH317\nH317\nAquatic Acute 1\nH400\nAquatic Chronic 1\nH410\nH410\n607-700-00-0\nindoxacarb (ISO);\nmethyl (4aS)-7-chloro-2-{(methoxycarbonyl)[4-(trifluoromethoxy)phenyl]carbamoyl}-2,5-dihydroindeno[1,2-e][1,3,4]oxadiazine-4a(3H)-carboxylate [1]\n173584-44-6 [1]\nAcute Tox. 3\nH301\nGHS06\nH301\nM = 1\nM = 1\nAcute Tox. 4\nH332\nGHS08\nH332\nSTOT RE 1\nH372 (blood, nervous system, heart)\nGHS09\nH372 (blood, nervous system, heart)\nSkin Sens. 1B\nH317\nDgr\nH317\nAquatic Acute 1\nH400\nAquatic Chronic 1\nH410\nH410\nreaction mass of (S)- Indoxacarb and (R)- Indoxacarb 75:25;\nmethyl 7-chloro-2-{(methoxycarbonyl)[4-(trifluoromethoxy)phenyl]carbamoyl}-2,5-dihydroindeno[1,2-e][1,3,4]oxadiazine-4a(3H)-carboxylate [2]\n144171-61-9 [2]\n607-702-00-1\ndihexyl phthalate\n201-559-5\n84-75-3\nRepr. 1B\nH360FD\nGHS08\nDgr\nH360FD\n607-703-00-7\nammoniumpentadeca- fluorooctanoate\n223-320-4\n3825-26-1\nCarc. 2\nH351\nGHS08\nH351\nRepr. 1B\nH360D\nGHS07\nH360D\nLact.\nH362\nGHS05\nH362\nAcute Tox. 4\nH332\nDgr\nH332\nAcute Tox. 4\nH302\nH302\nSTOT RE 1\nH372 (liver)\nH372 (liver)\nEye Dam.1\nH318\nH318\n607-704-00-2\nperfluorooctanoic acid\n206-397-9\n335-67-1\nCarc. 2\nH351\nGHS08\nH351\nRepr. 1B\nH360D\nGHS07\nH360D\nLact.\nH362\nGHS05\nH362\nAcute Tox. 4\nH332\nDgr\nH332\nAcute Tox. 4\nH302\nH302\nSTOT RE 1\nH372 (liver)\nH372 (liver)\nEye Dam. 1\nH318\nH318\n612-282-00-8\noctadecylamine\n204-695-3\n124-30-1\nAsp. Tox. 1\nH304\nGHS05\nH304\nM = 10\nM = 10\nSTOT RE 2\nH373 (gastro-intestinal tract, liver, immune system)\nGHS08\nH373 (gastro-intestinal tract, liver, immune system)\nSkin Irrit. 2\nH315\nGHS09\nH315\nEye Dam. 1\nH318\nDgr\nH318\nAquatic Acute 1\nH400\nAquatic Chronic 1\nH410\nH410\n612-283-00-3\n(Z)-octadec-9-enylamine\n204-015-5\n112-90-3\nAcute Tox. 4\nH302\nGHS05\nH302\nM = 10\nM = 10\nAsp Tox. 1\nH304\nGHS07\nH304\nSTOT SE 3\nH335\nGHS08\nH335\nSTOT RE 2\nH373 (gastro-intestinal tract, liver, immune system)\nGHS09\nH373 (gastro-intestinal tract, liver, immune system)\nSkin Corr. 1B\nH314\nDgr\nH314\nAquatic Acute 1\nH400\nAquatic Chronic 1\nH410\nH410\n612-284-00-9\namines, hydrogenated tallow alkyl\n262-976-6\n61788-45-2\nAsp Tox. 1\nH304\nGHS08\nH304\nM = 10\nM = 10\nSTOT RE 2\nH373 (gastro-intestinal tract, liver, immune system)\nGHS05\nH373 (gastro-intestinal tract, liver, immune system)\nSkin Irrit. 2\nH315\nGHS09\nH315\nEye Dam. 1\nH318\nDgr\nH318\nAquatic Acute 1\nH400\nAquatic Chronic 1\nH410\nH410\n612-285-00-4\namines, coco alkyl\n262-977-1\n61788-46-3\nAcute Tox. 4\nH302\nGHS05\nH302\nM = 10\nM = 10\nAsp. Tox. 1\nH304\nGHS07\nH304\nSTOT SE 3\nH335\nGHS08\nH335\nSTOT RE 2\nH373 (gastro-intestinal tract, liver, immune system)\nGHS09\nH373 (gastro-intestinal tract, liver, immune system)\nSkin Corr. 1B\nH314\nDgr\nH314\nAquatic Acute 1\nH400\nAquatic Chronic 1\nH410\nH410\n612-286-00-X\namines, tallow alkyl\n263-125-1\n61790-33-8\nAcute Tox. 4\nH302\nGHS05\nH302\nM = 10\nM = 10\nAsp. Tox. 1\nH304\nGHS07\nH304\nSTOT RE 2\nH373 (gastro-intestinal tract, liver, immune system)\nGHS08\nH373 (gastro-intestinal tract, liver, immune system)\nSkin Corr. 1B\nH314\nGHS09\nH314\nAquatic Acute 1\nH400\nDgr\nAquatic Chronic 1\nH410\nH410\n616-206-00-4\nflufenoxuron (ISO);\n1-(4-(2-cloro-α,α,α-p-trifluorotolyloxy)-2-fluorophenyl)-3-(2,6-difluorobenzolyl)urea\n417-680-3\n101463-69-8\nLact.\nH362\nGHS09\nH362\nM = 10 000\nM = 10 000\nAquatic Acute 1\nH400\nWng\nAquatic Chronic 1\nH410\nH410\n616-207-00-X\npolyhexamethylene biguanide hydrochloride\n27083-27-8 or 32289-58-0\nCarc. 2\nH351\nGHS05\nH351\nM = 10\nM = 10\nAcute Tox. 4\nH302\nGHS07\nH302\nSTOT RE 1\nH372 (respiratory tract) (inhalation)\nGHS08\nH372 (respiratory tract) (inhalation)\nEye Dam. 1\nH318\nGHS09\nH318\nSkin Sens. 1B\nH317\nDgr\nH317\nAquatic Acute 1\nH400\nAquatic Chronic 1\nH410\nH410\n616-208-00-5\nN-ethyl-2-pyrrolidone;\n1-ethylpyrrolidin-2-one\n220-250-6\n2687-91-4\nRepr. 1B\nH360D\nGHS08\nDgr\nH360D\n616-209-00-0\namidosulfuron (ISO);\n3-(4,6-dimethoxypyrimidin-2-yl)-1-((N-methyl-N-methylsulfonylamino)sulfonyl)urea\n407-380-0\n120923-37-7\nAquatic Acute 1\nH400\nGHS09\nM = 100\nM = 100\nAquatic Chronic 1\nH410\nWng\nH410\n616-210-00-6\ntebufenpyrad (ISO);\nN-(4-tertbutylbenzyl)-4-chloro-3-ethyl-1-methyl-1Hpyrazole-5- carboxamide\n119168-77-3\nAcute Tox. 3\nH301\nGHS06\nH301\nM = 10\nM = 10\nAcute Tox. 4\nH332\nGHS08\nH332\nSTOT RE 2\nH373 (gastro-intestinal tract) (Oral)\nGHS09\nH373 (gastro-intestinal tract) (Oral)\nSkin Sens. 1B\nH317\nDgr\nH317\nAquatic Acute 1\nH400\nAquatic Chronic 1\nH410\nH410\n616-211-00-1\nproquinazid (ISO);\n6-iodo-2-propoxy-3-propylquinazolin-4(3H)-one\n189278-12-4\nCarc. 2\nH351\nGHS08\nH351\nM = 1\nM = 10\nAquatic Acute 1\nH400\nGHS09\nAquatic Chronic 1\nH410\nWng\nH410",
  "extent": "E+W+S+N.I.",
  "status": null,
  "version": "current",
  "annotations": [],
  "outstanding_effects": [],
  "provenance": {
    "source": "legislation.gov.uk",
    "source_url": "https://www.legislation.gov.uk/eur/2013/944/annex/III",
    "retrieved_at": "2026-11-01T14:48:22.930867+00:00"
  },
  "licence": "Open Government Licence v3.0",
  "licence_url": "https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/",
  "attribution": "Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives."
}